Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N. Moore, Bradley J. Monk, Andrea E. Wahner Hendrickson et al.|The Lancet Oncology|2019Cited by 533
Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancerMelissa Khaw, Jeffrey S. Miller, Nicholas A. Zorko et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 8
Bypassing NK cell limitations in the tumor microenvironment through novel Poly-Antigen Cytokine Complexes 2287Martin Felices, Jeffrey S. Miller, Melissa Khaw et al.|The Journal of Immunology|2025Cited by 0